An Unbiased View of BMS-199264 hydrochloride
All enrolled individuals who gained at the least one dose of zosuquidar or placebo all through induction have been monitored with the prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The commonest adverse functions were linked to the period of prolonged and significant myelosuppression as is predicted with indu